PracticeUpdate: Haematology & Oncology

VOL. 1 • No. 5 • 2016

RESEARCH NEWS AND VIEWS FROM ELSEVIER

FORMERLY HAEMATOLOGY & ONCOLOGY NEWS

OPINION

When you put me in a hospital gown, I ampowerless. Because a patient’s sitting there nodding their head doesn’t mean they understand a singleword. 27

Cabozantinib has potential to become first-line treatment for renal cell carcinoma

CONFERENCE ESMO 2016

Improvement in progression- free survival with ribociclib + letrozole may represent a paradigm shift in advanced breast cancer 5 HER2+ and ER+ breast cancer trials 9 Metastatic renal cell carcinoma review 12 Current concepts in managing rare histologies in bladder cancer 13 BREAST Current challenges in breast

Cabozantinib improved progression-free survival and the response rate versus sunitinib significantly in a phase 2 multicentre trial in patients with metastatic renal cell carcinoma. 5

cancer management in developing countries

17

KIDNEY Adjuvant therapy in RCC was thought a dead question, thus this positive trial was a surprise for many 24

COLON & RECTUM Primary tumour location

predicts response to therapy for RAS WT

25

Readers Poll Are you interested

to become a member of

Elsevier’s Medical Advisory Board? Scan this code or go to goo.gl/V4KLLq to have your say in this issue’s PracticeUpdate Haematology & Oncology Readers Poll.

Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups Breast Cancer Research These findings support the prognostic value of automated Ki67 scoring in breast cancer.

Topotecan plus carboplatin vs standard platinum-based combinations in platinum-sensitive recurrent ovarian cancer Annals of Oncology The authors concluded that TC was well-tolerated and feasible in relapsed, platinum-sensitive ovarian cancer patients, but it did not reduce PFS or OS compared with standard platinum doublets in this population.

Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH- mutant glioma Journal of Clinical Oncology The study results showed that measuring 2HG concentration by MRS is reproducible and that measuring 2HG concentration reliably reports on glioma disease state. 22

Long-term follow-up of the French Stop Imatinib (STIM1) Study in CML Journal of Clinical Oncology

Patients with CML who achieve undetectable MRD can safely discontinue imatinib with close molecular surveillance. Although most will relapse, some patients will have sustained molecular responses without therapy. 26

16

18

Made with